- Sona Nanotech (CSE:SONA) has revealed that its targeted hyperthermia therapy (THT) has shown positive results in a second preclinical cancer model
- The company’s therapy has shown promising results in treating melanoma in preclinical trials following successful responses from its triple-negative breast cancer study
- THT demonstrated it effectively treated melanoma tumors in animal models when administered on its own
- Shares of Sona Nanotech are up 3.33 per cent to C$0.31 as of 9:45 a.m. ET
Sona Nanotech (CSE:SONA) has revealed that its targeted hyperthermia therapy (THT) has shown positive results in a second preclinical cancer model.
In a press release, the company said that its therapy has shown promising results in treating melanoma in preclinical trials following successful responses from its triple-negative breast cancer study.
THT demonstrated it effectively treated melanoma tumors in animal models when administered on its own.
“Demonstrating the efficacy of our therapy in a second type of solid cancer in our preclinical efficacy study highlights the potential for Sona’s therapy to be applied to multiple solid cancer types in humans,” David Regan, CEO of Sona Nanotech, said in a press release. “Our initial indication in humans is intended to be for late-stage, irresectable melanoma —— a type of cancer for which few current therapies have any effect —— so these most recent data are important and very encouraging to our efforts to get Sona’s therapy into the clinic.”
Additionally, the second cancer model portion of the study showed that in cohort of seven animals, 100 per cent of treated melanoma cancer mouse tumors bearing gold nanorods and IL-2 responded to the combination therapy, effectively resulting in resulting in a flattening of the tumor growth curves.
Sona Nanotech is headquartered out of Halifax, Nova Scotia and is a company developing Targeted Hyperthermia™, a photothermal cancer therapy, which uses therapeutic heat to treat solid cancer tumors.
Shares of Sona Nanotech are up 3.33 per cent to C$0.31 as of 9:45 a.m. ET.
Join the discussion: Find out what everybody’s saying about this stock on the SonaNanotech Bullboard investor discussion forum, and check out the rest of Stockhouse’s stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
